Thrivent Financial for Lutherans Sells 3,069 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Thrivent Financial for Lutherans reduced its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 2.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 116,123 shares of the biotechnology company’s stock after selling 3,069 shares during the period. Thrivent Financial for Lutherans owned approximately 0.07% of Ironwood Pharmaceuticals worth $757,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of IRWD. 13D Management LLC increased its holdings in Ironwood Pharmaceuticals by 971.8% in the 4th quarter. 13D Management LLC now owns 367,649 shares of the biotechnology company’s stock valued at $4,206,000 after acquiring an additional 333,348 shares during the last quarter. Hotchkis & Wiley Capital Management LLC increased its holdings in Ironwood Pharmaceuticals by 4.0% in the 4th quarter. Hotchkis & Wiley Capital Management LLC now owns 1,140,470 shares of the biotechnology company’s stock valued at $13,047,000 after acquiring an additional 43,800 shares during the last quarter. Parkman Healthcare Partners LLC increased its holdings in Ironwood Pharmaceuticals by 20.7% in the 4th quarter. Parkman Healthcare Partners LLC now owns 120,652 shares of the biotechnology company’s stock valued at $1,380,000 after acquiring an additional 20,652 shares during the last quarter. Eventide Asset Management LLC bought a new stake in Ironwood Pharmaceuticals in the 4th quarter valued at $8,472,000. Finally, Gerber LLC bought a new stake in Ironwood Pharmaceuticals in the 4th quarter valued at $316,000.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on IRWD shares. StockNews.com upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, July 16th. Leerink Partners started coverage on shares of Ironwood Pharmaceuticals in a report on Monday, September 9th. They issued a “market perform” rating and a $5.00 target price on the stock. Leerink Partnrs upgraded shares of Ironwood Pharmaceuticals to a “hold” rating in a report on Monday, September 9th. Craig Hallum reduced their target price on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Finally, Wells Fargo & Company reduced their target price on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $12.17.

Ironwood Pharmaceuticals Trading Down 6.7 %

IRWD stock opened at $4.01 on Tuesday. Ironwood Pharmaceuticals, Inc. has a 12 month low of $3.79 and a 12 month high of $15.70. The company has a 50-day moving average price of $4.75 and a 200 day moving average price of $6.23. The stock has a market cap of $627.68 million, a PE ratio of -0.59 and a beta of 0.48.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, insider Minardo John sold 9,910 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $4.27, for a total value of $42,315.70. Following the completion of the sale, the insider now directly owns 284,661 shares of the company’s stock, valued at $1,215,502.47. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.90% of the stock is owned by corporate insiders.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.